🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. PF-07275315 dose 1

    Pfizer

    Moderate to Severe Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  2. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Biotech Pharmaceutical Co.,

    Influenza

    phase 3 mab active

    1 trial

  3. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Sinovac Research and Development Co.,

    Influenza

    phase 3 mab active

    1 trial

  4. Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  5. Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  6. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial

  7. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial

  8. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  9. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  10. Pregabalin Dose Level 1

    Pfizer

    Partial Onset Seizures

    phase 3 small molecule completed

    1 trial

  11. RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

  12. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  13. SPD489 Low-Dose

    Takeda

    Negative Symptoms of Schizophrenia

    phase 3 small molecule terminated

    1 trial

  14. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  15. Sotagliflozin Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  16. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  17. TD-1473 Dose A

    Theravance Biopharma Ireland Umited

    Ulcerative Colitis (UC)

    phase 3 small molecule terminated

    2 trials

  18. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  19. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  20. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 3 mab completed

    1 trial

  21. Treatment of edaravone dexborneol sublingual tablets containin edaravone 30 mg plus borneol 6 mg, twice daily (with an interval of ≥6 hours between doses) for three months.

    The First People's Hospital of Lianyungang

    Post-stroke Epilepsy

    phase 3 small molecule active

    1 trial

  22. Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  23. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo Nordisk A/S

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  24. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources